The popularity of Sildenafil initially fueled a surge for the drug industry, but recent shifts present a uncertain scenario for shareholders. Off-patent versions are reducing profits, and persistent patent challenges https://dawudagif452365.topbloghub.com/47753390/the-blue-pill-and-big-pharma-a-precarious-play